Monteverde Law Firm Investigates RE/MAX Sale to The Real Brokerage
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy RMAX?
Source: Globenewswire
- Shareholder Rights Protection: Monteverde & Associates is investigating the transaction between RE/MAX Holdings, Inc. and The Real Brokerage Inc., where RE/MAX shareholders are expected to receive either 5.152 shares of the combined company or $13.80 in cash per share, raising questions about the fairness of the deal.
- Firm's Reputation: The firm has been recognized as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, highlighting its strong capabilities and successful track record in protecting shareholder rights.
- Extensive Litigation Experience: Headquartered in the Empire State Building, Monteverde & Associates has a proven history of litigating in various courts, including the U.S. Supreme Court, showcasing its expertise in handling complex securities cases.
- Free Consultation Services: The firm offers free consultations, encouraging RE/MAX shareholders with concerns about the transaction to reach out to a lawyer, ensuring they receive necessary information and support.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RMAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RMAX
Wall Street analysts forecast RMAX stock price to fall
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 9.940
Low
9.00
Averages
9.00
High
9.00
Current: 9.940
Low
9.00
Averages
9.00
High
9.00
About RMAX
RE/MAX Holdings, Inc. is a franchisor in the real estate industry, franchising real estate brokerages globally under the REMAX brand, and mortgage brokerages within the United States under the Motto Mortgage brand. Its segments include Real Estate, Mortgage, and Marketing Funds. Real Estate segment comprises the operations of the Company's owned and independent global franchising operations under the RE/MAX brand along with corporate-wide shared services expenses. The mortgage segment comprises the operations of the Company’s mortgage brokerage franchising operations under the Motto brand and mortgage loan processing services under the wemlo brand. The Motto franchise model offers United States real estate brokers, mortgage professionals and other investors access to the mortgage brokerage industry. Marketing Funds segment comprises the operations of its marketing campaigns designed to build and maintain brand awareness and the development and operation of agent marketing technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation Launched into RE/MAX Holdings' Merger Deal
- Investigation Initiated: Bleichmar Fonti & Auld LLP has announced an investigation into RE/MAX Holdings, Inc. and its board, focusing on potential breaches of fiduciary duties to shareholders in connection with the merger with The Real Brokerage Inc.
- Merger Details Revealed: On April 27, 2026, RE/MAX announced its agreement to be acquired by The Real Brokerage, allowing shareholders to choose between $13.80 in cash per share or 5.15 shares of the post-merger entity, raising concerns about the fairness of the merger price.
- Shareholder Rights Protection: The investigation aims to determine whether the merger was executed at an unfairly low price and whether insiders at RE/MAX are receiving potentially unfair benefits not shared with public shareholders, which could impact shareholder returns.
- Legal Options Available: Current RE/MAX shareholders are encouraged to submit their information for legal support, with BFA offering representation on a contingency fee basis, emphasizing the firm's commitment to protecting shareholder interests.
See More
Monteverde Law Firm Investigates RE/MAX Sale to The Real Brokerage
- Shareholder Rights Protection: Monteverde & Associates is investigating the transaction between RE/MAX Holdings, Inc. and The Real Brokerage Inc., where RE/MAX shareholders are expected to receive either 5.152 shares of the combined company or $13.80 in cash per share, raising questions about the fairness of the deal.
- Firm's Reputation: The firm has been recognized as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, highlighting its strong capabilities and successful track record in protecting shareholder rights.
- Extensive Litigation Experience: Headquartered in the Empire State Building, Monteverde & Associates has a proven history of litigating in various courts, including the U.S. Supreme Court, showcasing its expertise in handling complex securities cases.
- Free Consultation Services: The firm offers free consultations, encouraging RE/MAX shareholders with concerns about the transaction to reach out to a lawyer, ensuring they receive necessary information and support.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE: OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may infringe on shareholder rights.
- Shareholder Rights Protection: The firm is also scrutinizing XOMA Royalty Corporation (NASDAQ: XOMA)'s sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, urging shareholders to understand their legal rights and options.
- RE/MAX Transaction Review: RE/MAX Holdings, Inc. (NYSE: RMAX) is set to sell to The Real Brokerage Inc. for either 5.152 shares or $13.80 in cash per share, with Halper Sadeh LLC warning shareholders about terms that may limit superior competing offers.
- Soleno Shareholder Rights: Soleno Therapeutics, Inc. (NASDAQ: SLNO) is selling to Neurocrine Biosciences for $53.00 per share in cash, and Halper Sadeh LLC encourages shareholders to learn about their legal rights and potential remedies.
See More
U.S. Stocks Decline Amid Geopolitical Tensions and Earnings Strength
- Geopolitical Tensions: Stalled peace negotiations between the U.S. and Iran have led to rising oil prices, raising fresh concerns about inflation and global economic growth, as investors balance strong corporate earnings against geopolitical uncertainties.
- Earnings Performance: Verizon (VZ) reported a better-than-expected Q1, while Domino's Pizza (DPZ) posted disappointing results and announced an additional $1 billion share repurchase program, highlighting the varied market reactions to different companies.
- Acquisition Activity: Shell (SHEL) agreed to acquire ARC Resources (AETUF) for C$32.80 per share, while China blocked Meta's (META) acquisition of AI startup Manus, reflecting the complexities of the global M&A landscape.
- Market Index Fluctuations: Near midday, the Dow was down 0.25%, the Nasdaq down 0.28%, and the S&P 500 down 0.14%, indicating the market's sensitive response to geopolitical tensions and economic data.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE:OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may involve breaches of fiduciary duties impacting shareholder confidence and company reputation.
- RE/MAX Transaction Scrutiny: The sale of RE/MAX Holdings, Inc. (NYSE:RMAX) to The Real Brokerage Inc. offers either 5.152 shares or $13.80 in cash per share, potentially limiting superior competing offers, prompting shareholders to consider their rights and options.
- XOMA Transaction Risks: XOMA Royalty Corporation (NASDAQ:XOMA) is involved in a sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC possibly seeking increased compensation for shareholders, affecting the future shareholder structure of the company.
- Merger Impact Analysis: The merger between The Real Brokerage Inc. (NASDAQ:REAX) and RE/MAX will result in Real shareholders owning approximately 59% of the combined entity, potentially altering the competitive landscape and necessitating a reassessment of shareholder rights and risks post-merger.
See More
Investigation Alerts for Multiple Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share in cash, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to treat shareholders fairly, potentially impacting shareholder rights.
- RE/MAX Acquisition Proposal: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations into whether the Board failed to handle the transaction fairly, affecting shareholder interests.
- Soleno Acquisition Investigation: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total transaction value of approximately $2.9 billion, but this price is below its 52-week high of $90.32, raising questions about the Board's fairness in the deal.
See More
Investigation Launched into RE/MAX Holdings' Merger Deal
- Investigation Initiated: Bleichmar Fonti & Auld LLP has announced an investigation into RE/MAX Holdings, Inc. and its board, focusing on potential breaches of fiduciary duties to shareholders in connection with the merger with The Real Brokerage Inc.
- Merger Details Revealed: On April 27, 2026, RE/MAX announced its agreement to be acquired by The Real Brokerage, allowing shareholders to choose between $13.80 in cash per share or 5.15 shares of the post-merger entity, raising concerns about the fairness of the merger price.
- Shareholder Rights Protection: The investigation aims to determine whether the merger was executed at an unfairly low price and whether insiders at RE/MAX are receiving potentially unfair benefits not shared with public shareholders, which could impact shareholder returns.
- Legal Options Available: Current RE/MAX shareholders are encouraged to submit their information for legal support, with BFA offering representation on a contingency fee basis, emphasizing the firm's commitment to protecting shareholder interests.
See More
Monteverde Law Firm Investigates RE/MAX Sale to The Real Brokerage
- Shareholder Rights Protection: Monteverde & Associates is investigating the transaction between RE/MAX Holdings, Inc. and The Real Brokerage Inc., where RE/MAX shareholders are expected to receive either 5.152 shares of the combined company or $13.80 in cash per share, raising questions about the fairness of the deal.
- Firm's Reputation: The firm has been recognized as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, highlighting its strong capabilities and successful track record in protecting shareholder rights.
- Extensive Litigation Experience: Headquartered in the Empire State Building, Monteverde & Associates has a proven history of litigating in various courts, including the U.S. Supreme Court, showcasing its expertise in handling complex securities cases.
- Free Consultation Services: The firm offers free consultations, encouraging RE/MAX shareholders with concerns about the transaction to reach out to a lawyer, ensuring they receive necessary information and support.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE: OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may infringe on shareholder rights.
- Shareholder Rights Protection: The firm is also scrutinizing XOMA Royalty Corporation (NASDAQ: XOMA)'s sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, urging shareholders to understand their legal rights and options.
- RE/MAX Transaction Review: RE/MAX Holdings, Inc. (NYSE: RMAX) is set to sell to The Real Brokerage Inc. for either 5.152 shares or $13.80 in cash per share, with Halper Sadeh LLC warning shareholders about terms that may limit superior competing offers.
- Soleno Shareholder Rights: Soleno Therapeutics, Inc. (NASDAQ: SLNO) is selling to Neurocrine Biosciences for $53.00 per share in cash, and Halper Sadeh LLC encourages shareholders to learn about their legal rights and potential remedies.
See More
U.S. Stocks Decline Amid Geopolitical Tensions and Earnings Strength
- Geopolitical Tensions: Stalled peace negotiations between the U.S. and Iran have led to rising oil prices, raising fresh concerns about inflation and global economic growth, as investors balance strong corporate earnings against geopolitical uncertainties.
- Earnings Performance: Verizon (VZ) reported a better-than-expected Q1, while Domino's Pizza (DPZ) posted disappointing results and announced an additional $1 billion share repurchase program, highlighting the varied market reactions to different companies.
- Acquisition Activity: Shell (SHEL) agreed to acquire ARC Resources (AETUF) for C$32.80 per share, while China blocked Meta's (META) acquisition of AI startup Manus, reflecting the complexities of the global M&A landscape.
- Market Index Fluctuations: Near midday, the Dow was down 0.25%, the Nasdaq down 0.28%, and the S&P 500 down 0.14%, indicating the market's sensitive response to geopolitical tensions and economic data.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE:OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may involve breaches of fiduciary duties impacting shareholder confidence and company reputation.
- RE/MAX Transaction Scrutiny: The sale of RE/MAX Holdings, Inc. (NYSE:RMAX) to The Real Brokerage Inc. offers either 5.152 shares or $13.80 in cash per share, potentially limiting superior competing offers, prompting shareholders to consider their rights and options.
- XOMA Transaction Risks: XOMA Royalty Corporation (NASDAQ:XOMA) is involved in a sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC possibly seeking increased compensation for shareholders, affecting the future shareholder structure of the company.
- Merger Impact Analysis: The merger between The Real Brokerage Inc. (NASDAQ:REAX) and RE/MAX will result in Real shareholders owning approximately 59% of the combined entity, potentially altering the competitive landscape and necessitating a reassessment of shareholder rights and risks post-merger.
See More
Investigation Alerts for Multiple Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share in cash, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to treat shareholders fairly, potentially impacting shareholder rights.
- RE/MAX Acquisition Proposal: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations into whether the Board failed to handle the transaction fairly, affecting shareholder interests.
- Soleno Acquisition Investigation: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total transaction value of approximately $2.9 billion, but this price is below its 52-week high of $90.32, raising questions about the Board's fairness in the deal.
See More
